Navigation Links
Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement

DUBLIN, Ohio, July 31 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced a three-year agreement with Prime Therapeutics, one of the nation's leading pharmacy benefit managers, to serve as its primary supply chain partner for branded and generic pharmaceuticals, effective August 1.

Prime Therapeutics managed more than $8.2 billion in prescription drug spend in 2007, and currently serves approximately 14.6 million members through Blue Cross and Blue Shield Plans, employer and union groups and third-party administrators.

"We look forward to delivering the pharmaceutical supply chain services that will help Prime Therapeutics continue to efficiently and effectively serve its patients' medication needs," said Mike Kaufmann, group president of Healthcare Supply Chain Services - Pharmaceutical for Cardinal Health. "This agreement is an excellent example of our commitment to building flexible, mutually beneficial partnerships with our customers that also enable us to grow our pharmaceutical distribution business."

Cardinal Health will also offer Prime Therapeutics additional supply chain optimization services to help improve its operational efficiency.

"This innovative new partnership will provide us with the benefits of buying through a drug wholesaler and the insights and expertise of direct generics buying," said Tim Dickman, Prime Therapeutics CEO. "Cardinal Health was selected as our primary distributor because they offer the experience, value-added services and flexibility that we need to continue to deliver quality, cost-efficient prescription drug benefits to our customers."

About Prime Therapeutics

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) electronic infection surveillance service, VIASYS(R) respiratory care products and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
2. New York Strengthens Emergency Preparedness with Cardinal Health Ventilators
3. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
4. Nanotechs health, environmental impacts worry scientists and the public
5. ETEX and LifeNet Health, Inc. Enter Agreement
6. IBF/LifeScience Alley MedTech Investing Conference Adds Ashley Boam, Acting Deputy Director for Science and Review Policy, Office of Device Evaluation, Center for Devices and Radiological Health, FDA
7. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
8. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
9. Primera Biosystems Raises $21 Million in Series B Private Round
10. Prime Therapeutics Receives VIPPS Accreditation
11. Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
Breaking Biology News(10 mins):